It is a well-known principle in vaccine science research. Atmar, MD, of Baylor College of Medicine, Houston, Texas, and Dr. The IDCRC trial, which began enrollment in May 2021, is led by Co-Chairs Robert L. Of those volunteers, 150 study participants received a booster of Johnson & Johnson’s Ad26.CoV2-S vaccine 154 received a booster of Moderna’s mRNA-1273 vaccine (100 microgram dose) and 154 received a booster of Pfizer-BioNTech’s BNT162b2. The NEJM report describes findings from 458 adult volunteers who had been fully vaccinated with one of the three EUA COVID-19 vaccines at least 12 weeks prior to enrollment. These findings are from an ongoing phase 1/2 trial conducted under the UMSOM’s VTEU as part of the IDCRC and sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health. The ability to use vaccines for boosting that are different from those used for the primary series – mix and matching – can simplify vaccine booster administration. The newly published study found that for adults who previously received a full regimen of any COVID-19 vaccine granted EUA or approved by the FDA, an additional booster dose of any of these vaccines was safe and prompted an immune response. The UMSOM Vaccine Treatment and Evaluation Unit (VTEU) is part of the Infectious Diseases Clinical Research Consortium (IDCRC) that investigated the mix-and-match boosters. IHV investigators Jennifer Husson, MD, MPH, Joel Chua, MD, and Angie Price, DNP, MSN, CRNP, worked with CVD faculty on this study. Meagan Deming, MD, PhD, Instructor of Medicine at the UMSOM, is Vice-Chair of the study, which is a collaboration between investigators at the UMSOM’s CVD and the Institute of Human Virology (IHV). The boosters provide an important tool to prevent severe disease, hospitalization, and death.” “Boosters are critical against emerging variants of concern, such as the Delta and Omicron variants. Lyke, who is also the Director of CVD’s Malaria Vaccine and Challenge Unit. “This study was pivotal in contributing knowledge about the safety and immune responses of mixing and matching primary vaccines and boosters,” said Dr. Food and Drug Administration’s (FDA) expert vaccine panel in October that led to the recommendation for mix-and-match booster doses following completion of Emergency Use Authorization (EUA) regimens. Lyke, MD, Professor of Medicine at UMSOM, is Co-Chair and site Principal Investigator for the study and presented data to the U.S. The preliminary clinical trial results, reported today in The New England Journal of Medicine, found that is safe and effective to receive boosters that are the same or a different one from the person’s primary vaccine(s). Newswise - BALTIMORE-A University of Maryland School of Medicine (UMSOM), Center for Vaccine Development and Global Health (CVD), expert is co-leading an ongoing study that was pivotal in recommending adults and teens receive booster COVID-19 shots of their choosing starting in fall 2021.
0 Comments
Leave a Reply. |